诺思格（北京）医药科技股份有限公司 2023年限制性股票激励计划实施考核管理办法 诺思格（北京）医药科技股份有限公司（以下简称"公司"）为推进公司稳健 发展，进一步建立健全公司长效激励机制，吸引和留住优秀人才，充分调动公司高 级管理人员、中层管理人员、核心技术/业务人员积极性，有效将股东利益、公司 利益和核心团队个人利益结合在一起，增强公司整体凝聚力，使各方共同关注公司 的长远发展，确保公司发展战略和经营目标的实现，公司拟实施2023年限制性股票 激励计划（以下简称"股权激励计划"或"限制性股票激励计划"）。 为保证股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司股权激励管理办法》《深圳证券交易所创业板股票上市规则 （2023年修订）》《深圳证券交易所创业板上市公司自律监管指南第1号——业务 办理（2023年2月修订）》等有关法律法规、规范性文件和《公司章程》《诺思格（ 北京）医药科技股份有限公司2023年限制性股票激励计划（草案）》的有关规定， 并结合公司的实际情况，特制定公司《2023年限制性股票激励计划实施考核管理办 法》（以下简称"本办法"）。 一、考核目的 ...

证券代码：301333 证券简称：诺思格 诺思格（北京）医药科技股份有限公司 投资者关系活动记录表 编号：2023-005 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （） 信达证券 金鹰基金 农银人寿 泰致资产 泰达宏利 中金基金 参与单位名称及 中加基金 人员姓名 时间 2023 年 05 月 10 日 地点 北京金融街丽思卡尔顿酒店 董事、副总经理：滕乐燕 上市公司接待人 证券事务代表：齐士坤 员姓名 1、国内医药研发、临床 CRO 外包宏观环境的变化情况？ 从去年三季度开始，我们观察到国内的临床试验需求端是 在一个逐步恢复的过程中，我们也逐渐的收到了更多的客户询 价和竞标的方面的需求，但同时在临床运营服务、数统服务以及 临床试验现场管理服务等多个业务版块的竞争也变得比较激 烈。 2、公司关于国际化的规划和部署情况？ 投资者关系活动 我们认为，海外临床药物研发的市场非常广阔，机遇也非常 多，这也是一家临床 CRO 公司想要发展壮大，必然要走的一个 主要内容介绍 方向。我们的国际化布局起步于美国子公司的设立，公司近几年 境外收 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders was ¥28,792,801.97, representing an increase of 7.63% from ¥26,751,469.21 year-on-year[5] - The basic and diluted earnings per share decreased by 18.64%, from ¥0.59 to ¥0.48[5] - Total operating revenue for Q1 2023 was CNY 160,932,583.88, a decrease of 5.7% compared to CNY 170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached CNY 28,678,469.89, an increase of 5.0% from CNY 27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] Cash Flow and Liquidity - The net cash flow from operating activities surged by 324.03%, reaching ¥17,791,127.98 compared to ¥4,195,764.85 in the previous year[14] - The cash and cash equivalents net increase was -¥203,432,426.29, a 229.38% increase in outflow compared to -¥61,761,996.01 in the previous year[14] - The company's cash and cash equivalents decreased to ¥1,318,869,376.19 from ¥1,522,301,802.48 at the beginning of the year, representing a decline of approximately 13.4%[21] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 year-over-year[30] - The net cash flow from investment activities was negative CNY 217,277,058.98, compared to negative CNY 17,572,346.41 in the same period last year, indicating a worsening position[30] - The total cash outflow from financing activities was CNY 2,884,230.04, compared to CNY 48,125,141.86 in the previous year, showing a significant reduction of about 94.0%[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,922,065,259.29, reflecting a 2.19% increase from ¥1,880,941,437.34 at the end of the previous year[5] - Total liabilities increased to CNY 299,243,667.60 in Q1 2023, compared to CNY 286,982,213.23 in Q1 2022, representing a rise of 4.4%[23] - The company's total assets as of Q1 2023 amounted to CNY 1,922,065,259.29, up from CNY 1,880,941,437.34 at the end of Q1 2022, indicating a growth of 2.2%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,657[15] - The number of shares held by the top 10 unrestricted shareholders includes significant stakes from entities such as the Macau Financial Management Bureau and Kuwait Investment Authority, with holdings of ¥853,506 and ¥849,312 respectively[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] Government Support and Other Income - The company received government subsidies amounting to ¥3,874,649.00, which contributed to the increase in other income by 470.83%[12] Research and Development - Research and development expenses for Q1 2023 were CNY 13,570,366.43, up from CNY 12,565,071.46 in Q1 2022, reflecting an increase of 8.0%[24] Financial Management - The company reported a significant increase in financial income, with investment income rising by 559.33% to ¥5,758,579.90 from ¥873,392.38 in the previous year[12] - The company's weighted average return on equity decreased to 1.80% from 6.14% in the previous year, a decline of 4.34%[5] - The company reported a decrease in financial expenses, with a net financial cost of CNY -1,081,831.83 in Q1 2023, compared to CNY 219,257.85 in Q1 2022[26] Operational Metrics - Operating costs for Q1 2023 were CNY 102,313,022.59, down from CNY 105,791,748.21 in the same period last year, reflecting a cost reduction of approximately 4.4%[24] - The company reported a cash inflow of CNY 153,077,038.71 from sales of goods and services, an increase from CNY 136,263,341.28 in the same quarter last year, representing an increase of approximately 12.7%[29] - The total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, indicating an increase of about 6.0%[30] Future Outlook - The company has not provided specific future guidance or performance outlook in this quarter's report[19] - The company has not disclosed any new product developments or technological advancements in this quarter[19] - There are no updates on market expansion or mergers and acquisitions in the current report[19] - The report indicates no changes in restricted shares during the quarter[19] Audit Information - The company did not conduct an audit for the first quarter report[31]

Financial Performance - The company's operating revenue for 2022 was ¥637,520,243.17, representing a 4.78% increase from ¥608,425,821.40 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥113,592,222.90, a 14.47% increase compared to ¥99,237,035.17 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥130,465,983.24, up 13.87% from ¥114,573,627.51 in 2021[21]. - The total assets at the end of 2022 amounted to ¥1,880,941,437.34, a significant increase of 177.64% from ¥677,471,603.55 at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were ¥1,587,985,580.78, reflecting a 275.83% increase from ¥422,531,037.54 at the end of 2021[21]. - The basic earnings per share for 2022 were ¥2.22, slightly up by 0.45% from ¥2.21 in 2021[21]. - The diluted earnings per share for 2022 were also ¥2.22, maintaining the same increase of 0.45% from ¥2.21 in 2021[21]. - The company reported a weighted average return on equity of 12.54% for 2022, down from 26.63% in 2021, indicating a decrease of 14.09%[21]. - The quarterly operating revenue for Q4 2022 was ¥169,334,232.02, showing a recovery from the previous quarters[23]. - The net profit attributable to shareholders in Q4 2022 was ¥29,747,636.27, indicating a positive trend in profitability towards the end of the year[23]. Dividend and Capital Reserves - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares to all shareholders, based on a total of 60,000,000 shares[3]. - The company will also increase capital reserves by converting 6 shares for every 10 shares held by shareholders[3]. Risk Management and Compliance - The management discussed potential risks and countermeasures in the section on future development outlook[3]. - The report outlines the company's commitment to transparency and legal responsibility for the information provided[3]. - The company emphasizes the importance of risk awareness for investors regarding future plans and forecasts[3]. - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons[3]. - The report is prepared in accordance with the relevant financial reporting standards and regulations[3]. Research and Development - The company has established a comprehensive R&D service system since its inception in 2008, focusing on clinical trial outsourcing services[34]. - The company aims to enhance its service capabilities in response to the rising internationalization of drug development and regulatory standards[33]. - The company emphasizes the importance of early identification of product viability and effective R&D strategies to meet market needs[32]. - The company has a strong focus on quality management and regulatory knowledge to assist clients in navigating complex industry environments[34]. - R&D expenses increased by 21.37% to ¥49,993,012.97, reflecting the company's commitment to innovation[60]. - The total R&D investment for 2022 was approximately ¥49.99 million, representing 7.84% of total revenue, an increase from 6.77% in 2021[62]. - The number of R&D personnel increased to 250 in 2022, up 16.28% from 215 in 2021, with a higher proportion of staff under 30 years old[62]. Market Expansion and Strategy - The company plans to undertake more international multi-center clinical research projects to compete directly with international CRO companies[87]. - The company is actively expanding its global footprint and innovating clinical trial technologies to meet international regulatory trends[51]. - The company focuses on providing comprehensive CRO services to global pharmaceutical enterprises, aiming to improve drug development success rates and reduce R&D risks[50]. - The company has ongoing projects focused on AI-assisted clinical trial design, aiming to enhance operational efficiency and attract early clients[60]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotech sector[119]. - Market expansion efforts include entering two new international markets, aiming for a 15% increase in market share by the end of 2023[118]. Corporate Governance - All board members attended the meeting to review the annual report[3]. - The board of directors consists of 9 members, including 3 independent directors, and held 8 meetings during the reporting period, adhering to legal and regulatory requirements[98]. - The supervisory board has 3 members, including 1 employee supervisor, and convened 6 meetings, all in compliance with legal and regulatory standards[99]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring no financial resources are misappropriated[104]. - The company has a governance structure that does not involve differential voting rights arrangements[112]. - The company is committed to maintaining the interests of minority shareholders and ensuring effective governance practices[137]. Employee Management - The company has established a complete and fair compensation management system to align employee interests with company performance, enhancing employee motivation[143]. - The company has implemented a training program to improve employee skills and efficiency, focusing on new employee orientation and ongoing education[144]. - The total number of employees at the end of the reporting period was 1,926, with 1,789 being technical personnel, representing approximately 92.9% of the workforce[142]. - The company has a total of 267 employees with a master's degree or higher, accounting for approximately 13.9% of the workforce[142]. Environmental and Social Responsibility - There were no reported environmental penalties or issues during the reporting period, indicating compliance with environmental regulations[158]. - The company aims to enhance its corporate culture, promoting values such as inclusivity, harmony, and professionalism[157]. - The company has not reported any significant actions regarding poverty alleviation or rural revitalization initiatives[163]. Future Outlook - Future outlook suggests a projected revenue growth of approximately 20% for 2023, driven by new product launches and market expansion strategies[116]. - The company is actively investing in R&D for new technologies, with a budget allocation of 5 million for the development of innovative pharmaceutical solutions[117]. - A new product line is expected to launch in Q3 2023, anticipated to contribute an additional 10% to overall revenue[120]. - The management team has undergone changes, with new appointments aimed at strengthening operational efficiency and strategic direction[121]. Shareholder Relations - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing[165]. - The company will not repurchase any shares that were issued prior to the public offering during the lock-up period[167]. - The company has fulfilled all commitments related to shareholding and lock-up periods as of the reporting date[165]. - The company reported a commitment to reduce shareholding after the lock-up period, with a maximum of 25% of shares held before the IPO to be sold within two years[174].

Financial Performance - The company's revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders increased by 7.63% to ¥28,792,801.97 from ¥26,751,469.21 year-on-year[5] - The basic earnings per share decreased by 18.64% to ¥0.48 from ¥0.59 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.7% compared to ¥170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached ¥28,678,469.89, an increase of 5.0% from ¥27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] - Basic and diluted earnings per share for the first quarter were CNY 0.48, down from CNY 0.59 in the previous year, indicating a decrease of about 18.6%[27] Cash Flow and Liquidity - The net cash flow from operating activities surged by 324.03% to ¥17,791,127.98, up from ¥4,195,764.85 in the previous year[14] - The company’s cash and cash equivalents decreased by 229.38% to -¥203,432,426.29, compared to -¥61,761,996.01 in the previous year, primarily due to increased cash outflows from investment activities[14] - The net increase in cash and cash equivalents for the quarter was -CNY 203,432,426.29, compared to -CNY 61,761,996.01 in the same period last year[30] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 year-over-year[30] - Cash outflow for investment activities was CNY 1,178,035,638.88, compared to CNY 201,445,738.79 in the previous year, resulting in a net cash flow from investment activities of -CNY 217,277,058.98[30] - The ending balance of cash and cash equivalents was CNY 1,317,740,627.75, down from CNY 299,533,862.88 at the end of the previous year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,922,065,259.29, reflecting a 2.19% increase from ¥1,880,941,437.34 at the end of the previous year[5] - Total liabilities increased to ¥299,243,667.60 in Q1 2023 from ¥286,982,213.23 in Q1 2022[23] - The company's total assets as of Q1 2023 amounted to ¥1,922,065,259.29, up from ¥1,880,941,437.34 in the previous year[23] - The total equity attributable to shareholders of the parent company was ¥1,616,942,691.17, compared to ¥1,587,985,580.78 in Q1 2022[23] Operational Metrics - Total operating costs for Q1 2023 were ¥135,498,900.38, slightly down from ¥136,102,405.20 in the previous year[24] - The total accounts receivable increased to ¥75,653,913.16 from ¥72,873,069.81, showing a growth of about 3.9%[21] - Inventory levels rose to ¥55,678,260.95 from ¥53,006,573.21, indicating an increase of approximately 5.0%[21] - The company reported cash received from sales of goods and services of CNY 153,077,038.71, an increase from CNY 136,263,341.28 in the prior year, reflecting a growth of approximately 12.3%[29] - Total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, indicating an increase of about 6.0%[30] Shareholder Relations and Governance - The number of shares held by the top ten unrestricted shareholders includes significant stakes from entities such as the Macau Monetary Authority and Kuwait Investment Authority, with holdings of ¥853,506.00 and ¥849,312.00 respectively[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] - The report indicates that there are no changes in restricted shares during the quarter[19] Strategic Focus and Future Outlook - The company is actively managing its financial assets, with a focus on optimizing liquidity and investment strategies[21] - The overall financial health of the company reflects a strategic approach to asset management and shareholder relations[21] - Future outlook includes potential market expansion and product development initiatives, although specific figures were not disclosed in the report[21] - Research and development expenses for Q1 2023 were ¥13,570,366.43, up from ¥12,565,071.46 in Q1 2022, indicating a focus on innovation[24] - The company did not report any new product launches or significant market expansion strategies during this quarter[31]

Financial Performance - The company's operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders increased by 7.63% to ¥28,792,801.97 from ¥26,751,469.21 year-on-year[5] - Basic earnings per share decreased by 18.64% to ¥0.48 from ¥0.59 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 160,932,583.88, a decrease of 5.7% compared to CNY 170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached CNY 28,678,469.89, an increase of 5.0% from CNY 27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] Cash Flow and Investments - The net cash flow from operating activities surged by 324.03% to ¥17,791,127.98, compared to ¥4,195,764.85 in the previous year[14] - The company reported a cash inflow of CNY 153,077,038.71 from sales of goods and services, an increase from CNY 136,263,341.28 in the previous year, reflecting an increase of about 12.3%[29] - The total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, representing an increase of approximately 6.0%[30] - The net cash flow from investment activities was negative CNY 217,277,058.98, compared to negative CNY 17,572,346.41 in the same period last year, indicating a worsening of approximately 1,136.5%[30] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 in the previous year, reflecting an increase of about 421.5%[30] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,922,065,259.29, reflecting a significant increase of 187.20% from ¥669,236,394.13 at the end of the previous year[5] - Total liabilities increased to CNY 299,243,667.60 in Q1 2023, compared to CNY 286,982,213.23 in Q1 2022[23] - The company's total assets as of Q1 2023 amounted to CNY 1,922,065,259.29, up from CNY 1,880,941,437.34 in the previous year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,657, with ACE UNION HOLDING holding 28.68% of the shares[15] - The first quarter report highlighted significant investments from major shareholders, including the Macau Monetary Authority and Kuwait Investment Authority, each holding approximately 1.42% of shares[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest being the Macau Monetary Authority with 853,506 shares[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] Financial Management - The company reported a significant increase in financial income, with a rise of 593.41% in financial expenses due to increased exchange gains and interest income[12] - Other income increased by 470.83% to ¥3,874,649.00, primarily due to government subsidies related to revenue[12] - The company is actively managing its financial assets, with a focus on optimizing liquidity and investment strategies[21] Future Outlook - Future outlook includes potential market expansion and new product development, although specific figures were not disclosed in the report[20]